Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Aug;84(2):272-4.
doi: 10.1038/clpt.2008.127. Epub 2008 Jun 25.

Economic evaluation of pharmacogenetic tests

A C Wu  1 , A L Fuhlbrigge
Affiliations

Economic evaluation of pharmacogenetic tests

A C Wu et al. Clin Pharmacol Ther. 2008 Aug.

Abstract

Ever since the sequencing of the human genome was completed, prediction of treatment response in terms of genetic variation has been seen as an important and achievable goal. Pharmacogenetics is the study of how genetic differences affect variation in response to medication. One potential goal of pharmacogenetics is to be able to deliver "personalized medicine" by making management decisions that optimize patient health outcomes based on a patient's genetic makeup. Pharmacogenetic tests have the potential to (i) predict intended response, the goal outcome of the medication; (ii) predict unintended response to the medication, such as adverse events; (iii) titrate medication dose; and (iv) inform the development of novel therapeutics.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

The authors declared no conflict of interest.

References

    1. Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med 344, 783–792 (2001). - PubMed
    1. Osoba D, Slamon DJ, Burchmore M & Murphy M Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J. Clin. Oncol 20, 3106–3113 (2002). - PubMed
    1. Bartlett J, Mallon E & Cooke T The clinical evaluation of HER-2 status: which test to use? J. Pathol 199, 411–417 (2003). - PubMed
    1. Hicks DG & Tubbs RR Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum. Pathol 36, 250–261 (2005). - PubMed
    1. Kabe KL & Kolesar JM Role of trastuzumab in adjuvant therapy for locally invasive breast cancer. Am. J. Health Syst. Pharm 63, 527–533 (2006). - PubMed

Publication types

MeSH terms